Solgar NAC Disease Interactions
There are 4 disease interactions with Solgar NAC (acetylcysteine).
Acetylcysteine (applies to Solgar NAC) hepatic encephalopathy
Major Potential Hazard, High plausibility. Applicable conditions: Hepatic Coma
The use of acetylcysteine should be discontinued in patients with encephalopathy due to hepatic failure to avoid further administration of nitrogenous substances.
Acetylcysteine (applies to Solgar NAC) asthma
Moderate Potential Hazard, Moderate plausibility.
Acetylcysteine should be used with caution in patients with asthma, or where there is a history of bronchospasm. Patients with asthma should be closely monitored during the initiation of and throughout acetylcysteine therapy.
Acetylcysteine (applies to Solgar NAC) fluid overload
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Fluid Retention
Intravenous administration of acetylcysteine can cause fluid overload, potentially resulting in hyponatremia, seizure and death. To avoid fluid overload, a diluted dose is recommended, especially in patients less than 40 kg and those requiring fluid restrictions (see dosage and administration recommended by manufacturers).
Acetylcysteine (applies to Solgar NAC) gastric hemorrhage
Moderate Potential Hazard, Moderate plausibility. Applicable conditions: Gastrointestinal Hemorrhage, Peptic Ulcer
The use of acetylcysteine may worsen vomiting. Patients with peptic ulcer disease should be evaluated for the risk of gastrointestinal hemorrhage. In the presence of gastric hemorrhage, the decision to administer this agent should take into consideration the benefits versus the risks to an individual patient.
Solgar NAC drug interactions
There are 3 drug interactions with Solgar NAC (acetylcysteine).
More about Solgar NAC (acetylcysteine)
- Check interactions
- Compare alternatives
- Side effects
- Dosage information
- During pregnancy or Breastfeeding
Related treatment guides
Drug Interaction Classification
Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
No interaction information available. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.